Furthermore, the INSIGHT study, an open-label, multicenter, randomized trial (14), evaluated 19 patients with advanced NSCLC who had previously failed EGFR-TKI therapy and exhibited MET amplification. This evidence concerns the gene EGFR and non-small cell lung carcinoma.